Sumitomo Mitsui Trust Group Reduces $43M in Gilead Sciences, Inc. ($GILD)
Key Points
- Sumitomo Mitsui Trust Group changed its Gilead Sciences, Inc. ($GILD) stake by 10.3% last quarter, cutting to 2,931,232 shares worth $368.95 million.
- Wall Street's consensus rating on $GILD is Buy and an average price target of $157.83.
- $GILD last traded around $125.87.
Sumitomo Mitsui Trust Group reduced its position in Gilead Sciences, Inc. ($GILD) by 10.3% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,931,232 shares of Gilead Sciences, Inc. after selling 337,885 shares during the quarter. Sumitomo Mitsui Trust Group's holdings in Gilead Sciences, Inc. were worth $368.95 million as of its most recent filing.
Gilead Sciences, Inc. ($GILD) Stock
Gilead Sciences, Inc. Earnings
Gilead Sciences, Inc. Dividend
Analysts Set New Price Targets
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.